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High doses of the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine
can elicit somatic signs resembling those associated with nicotine withdrawal in nicotine-
naïve adult rats. Understanding this phenomenon, and its possible modulation by acute
nicotine and age, could inform the use of mecamylamine as both an experimental tool
and potential pharmacotherapy for tobacco dependence and other disorders. This study
evaluated the ability of high-dosemecamylamine to elicit somatic signs in adolescent rats,
and the potential for acute nicotine pretreatment to potentiate this effect as previously
reported in adults. Single or repeated injections of mecamylamine (1.5 or 3.0 mg/kg, s.c.)
elicited somatic signs in nicotine-naïve adolescents, but this effect was not influenced
by 2 h pretreatment with acute nicotine (0.5 mg/kg, s.c.). In an initial evaluation of
the effects of age in this model, mecamylamine (2.25 mg/kg, s.c.) elicited somatic
signs in nicotine-naïve adolescents and adults. This effect was modestly enhanced
following acute nicotine injections in adults but not in adolescents, even when a higher
nicotine dose (1.0 rather than 0.5 mg/kg, s.c.) was used in adolescents to account
for age differences in nicotine pharmacokinetics. These studies are the first to show
that mecamylamine elicits somatic signs in nicotine-naïve adolescent rats, an effect
that should be considered when designing and interpreting studies examining effects
of high doses of mecamylamine in adolescents. Our findings also provide preliminary
evidence that these signs may be differentially modulated by acute nicotine pretreatment
in adolescents versus adults.
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INTRODUCTION
The non-selective nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine is commonly
used in preclinical models. For example, in a well-established model of antagonist-precipitated
nicotine withdrawal, low doses of mecamylamine elicit increases in somatic (physical) signs (e.g.,
abdominal constrictions, facial fasciculations) in rats receiving a chronic nicotine infusion without
affecting somatic signs in nicotine-naïve rats (e.g., Malin et al., 1994; Watkins et al., 2000; Malin
and Goyarzu, 2009). At high doses, mecamylamine can itself elicit somatic signs in nicotine-
naïve rats that resemble those associated with nicotine withdrawal (Malin et al., 1994; Harrison
et al., 2001; Wing and Shoaib, 2007; Guillem et al., 2008; Harris et al., 2013), as well as other
behavioral effects including suppression of operant responding (Levin et al., 2000; Vann et al., 2006),
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2391
Schmidt et al. Somatic signs in adolescent rats
cognitive effects (Levin et al., 1987, 2000; Sanders et al., 2010),
and aversion (Watkins et al., 2000; Guillem et al., 2008). These
effects of mecamylamine alone presumably reflect antagonism
of endogenous nAChRs, which are prominently expressed in
numerous brain areas that mediate behavior including the
ventral tegmental area, hippocampus, medial habenula, and
interpeduncular nucleus (Wada et al., 1989; Gotti et al., 2006,
2009; Fowler et al., 2008).
Understanding the effects of high doses ofmecamylamine alone
on somatic signs and other behaviors is important for several
reasons. First, these effects can complicate data interpretation in
preclinical models, such as when mecamylamine is being used
to modulate the effects of nicotine. Second, these effects may
be relevant to mecamylamine’s adverse side effects in humans
(e.g., constipation, dizziness) that limit mecamylamine’s use as a
potential treatment for tobacco dependence and other disorders
(e.g., Tourette’s syndrome) in humans (Shytle et al., 2002; Bacher
et al., 2009; Nickell et al., 2013). In addition to informing
the use of mecamylamine as both an experimental tool and
putative pharmacotherapy, studying the behavioral effects of
mecamylamine alone could also provide important basic scientific
knowledge on the function of the cholinergic system.
We recently reported that acute nicotine pretreatment
enhanced the ability of high doses of mecamylamine to
elicit somatic signs in adult rats (Harris et al., 2013). Given
that increased sensitivity to the effects of an antagonist in
subjects acutely exposed to drugs is classically interpreted as a
withdrawal effect (e.g., Adams and Holtzman, 1990; Easterling
and Holtzman, 1997; Schulteis et al., 1997; Cunningham et al.,
2014), this phenomenon may reflect the early development of the
nicotine withdrawal syndrome (Harris et al., 2013). Alternatively,
it could reflect a nicotine-mecamylamine interaction unrelated
to withdrawal. Regardless of its interpretation, this effect is of
interest because mecamylamine exposure occurs in the presence
of acute nicotine exposure in animal models (Cohen et al., 2003;
Liu et al., 2007; Struthers et al., 2009) and in human smokers
(McClernon and Rose, 2005; McKee et al., 2009).
It is well established that adolescent and adult rodents can differ
in their response to pharmacological manipulation of nAChRs
(e.g., Shram et al., 2006, 2008a; Torres et al., 2008). For example,
adolescents exhibit attenuated somatic signs compared to adults
during mecamylamine-precipitated withdrawal from a chronic
nicotine infusion (O’Dell et al., 2004, 2006; Shram et al., 2008b).
To our knowledge, no studies have evaluated effects of high-dose
mecamylamine on somatic signs in drug-naïve adolescent rats, or
modulation of these effects by acute nicotine pretreatment.
The primary goal of this study was to evaluate effects of acute
mecamylamine, nicotine, and their combination on somatic signs
in adolescent rats using the same protocol previously studied in
adults (Harris et al., 2013). A secondary goal was to examine age
differences in these effects. Therefore, following establishment of
nicotine dosing conditions that accounted for age differences in
nicotine pharmacokinetics (see Vieira-Brock et al., 2013; Craig
et al., 2014) and produced similar nicotine serum levels across ages
(Experiment 2), we evaluated effects of mecamylamine alone and
mecamylamine combined with acute nicotine on somatic signs in
both adolescents and adults (Experiment 3).
MATERIALS AND METHODS
Animals
Experimentally naïve male Wistar rats (Charles River
Laboratories, Wilmington, MA, USA) were housed individually
in a temperature- and humidity-controlled colony room under a
reversed 12-h light/dark cycle with free access to food and water.
Upon arrival in the colony, adult rats (PND 62–67) weighed
275–300 g and adolescent rats (PND 21–23) weighed < 50 g.
Rats were allowed a period of 2 weeks to acclimate to the
experimental housing after arrival and were gently handled for
approximately 5 min on each of 2 days before all experiments. All
testing was conducted during the dark (active) phase. With the
exception of the challenge test in Experiment 1, all procedures
in adolescent rats were conducted from PND 35–42 (i.e., during
mid- adolescence, Spear, 2000), the same age range used in
(O’Dell et al., 2004, 2006; Shram et al., 2008b). The age range for
adults in the current studies (i.e., PND 76–83) was also similar to
that used in these studies. All procedures were approved by The
Institutional Animal Care and Use Committee (IACUC) of the
Minneapolis Medical Research Foundation (protocol # 08–08)
in accordance with the 2011 NIH Guide for the Care and Use of
Laboratory Animals and the 2003 Guidelines for the Care and
Use of Mammals in Neuroscience and Behavioral Research. All
efforts were made to minimize animal suffering.
Drugs
Nicotine bitartrate or mecamylamine hydrochloride (Sigma
Chemical Co., St. Louis, MO, USA) was dissolved in sterile saline.
The pH of the nicotine solution was adjusted to 7.4 using NaOH.
Nicotine and mecamylamine doses are expressed as the base and
salt, respectively. All injections were administered s.c. in a volume
of 1.0 ml/kg.
Experiment 1: Effects of Mecamylamine,
Nicotine, and Their Combination on
Somatic Signs in Adolescents
Protocol
The procedure was identical to that previously used to study the
effects of acute mecamylamine, nicotine, and their combination
on somatic signs in adult rats (Harris et al., 2013). On the first test
day, adolescent rats (PND 35–37) were injected with saline (Sal)
or 0.5 mg/kg nicotine (Nic 0.5). 1 h 50min after the first injection,
animals were injected with 0, 1.5, or 3.0 mg/kg mecamylamine
(i.e., Sal, Mec 1.5, or Mec 3.0) and, 10 min later, tested for somatic
signs as described below. This procedure was repeated across 5
consecutive days, with rats receiving the same treatment each
day. To examine the persistence of any sensitization-like effects
observed during the 5-day protocol, rats were re-tested under the
same conditions following a 7-day drug-free period (challenge
test). The following 6 groups were used: Nic 0.5+Mec 3.0 (n= 4),
Nic 0.5 + Mec 1.5 (n = 6), Nic 0.5 + Sal (n = 6), Sal + Mec 3.0
(n = 4), Sal +Mec 1.5 (n= 5), Sal + Sal (n= 6).
Assessment of Somatic Signs
During each test session, rats were placed in a clear plastic
container located in a quiet, lit room and videotaped for
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10 min. Test sessions were later scored for somatic signs
by a trained, blinded observer using a validated checklist as
described previously (Harris et al., 2011, 2013; Manbeck et al.,
2014). Individual categories of somatic signs included abdominal
constrictions (writhes and gasps), shakes and tremors, blinks, and
other miscellaneous signs including facial fasciculation, yawns,
and ptosis. If present continuously, facial fasciculations were
scored once every 15 s and ptosis once per minute.
Experiment 2: Serum and Brain Nicotine
Levels in Adolescents and Adults Following
Acute Nicotine
Protocol
Adolescent (PND 35–37) or adult (PND 76–81) rats were injected
with 0.5 mg/kg nicotine (n = 8 per age group) or 1.0 mg/kg
nicotine (adolescents only, n = 8). 1 h 50 min later, rats
were anesthetized with i.m. droperidol (2.0 mg/kg)/fentanyl
(0.04 mg/kg). 10 min later, rats were decapitated and trunk blood
and brain were collected. Timing of sample collection (relative
to nicotine injection) coincided with the timing of somatic sign
testing in Experiments 1 and 3.
Nicotine Assay
Serum and brain nicotine levels were measured using gas
chromatography with nitrogen-phosphorous detection (Jacob
et al., 1981). Brain nicotine levels were corrected for brain blood
content (Hieda et al., 1999).
Experiment 3: Effects of Mecamylamine
Alone and Mecamylamine Combined with
Nicotine on Somatic Signs in Adolescents
and Adults
Adolescent (PND 35–37) and adult (PND 76–81) rats were
injected with saline, 0.5 mg/kg nicotine (adults only), or
1.0 mg/kg nicotine (adolescents only). 1 h 50 min later, rats
were administered mecamylamine (0 or 2.25 mg/kg, s.c.) and,
10 min later, tested for somatic signs as described above. This
procedure was repeated 48 h later (2 test sessions total). These
nicotine doses were used because they produced similar serum
nicotine levels in adolescents and adults in Experiment 2. We
previously found that acute nicotine pretreatment potentiated
the effects of 3.0 mg/kg mecamylamine on somatic signs in
adults (Harris et al., 2013), We used a lower (2.25 mg/kg) dose
of mecamylamine in this study an attempt to avoid the robust
effects of 3.0 mg/kg mecamylamine in drug-naïve adolescents in
Experiment 1 (see Sal + Mec 3.0 group in Figure 1A), which
could create a ceiling effect that precluded potentiation of these
effects following nicotine pretreatment. Furthermore, pilot studies
indicated that acute nicotine pretreatment potentiated the effects
of 2.25 mg/kg mecamylamine on somatic signs in adults (data
not shown), supporting the use of this mecamylamine dose for
studying nicotine-mecamylamine interactions. We used a 2-day
procedure to expedite the protocol and to avoid the trend for the
effects of mecamylamine alone to increase in adolescents when a
5-day procedure was used (see Figures 1A,B), which could also
produce a ceiling effect. Adolescents were tested in the following
groups: Nic 1.0 +Mec 2.25 (n = 6), Sal +Mec 2.25 (n = 6), Nic
1.0 + Sal (n = 5), Sal + Sal (n = 6). Experimental groups for
adults were Nic 0.5 +Mec 2.25 (n = 9), Sal +Mec 2.25 (n = 9),
Sal + Sal (n = 6). A Nic 0.5 + Sal adult control group was not
included because we have previously shown that 2 h pretreatment
with 0.5 mg/kg nicotine alone does not affect somatic signs in
adults (Harris et al., 2013).
Statistical Analyses
Experiment 1
Total somatic signs during test sessions 1–5 were analyzed using
a two-factor ANOVA with group as a between-subject factor and
session as a within-subject factor, followed by Bonferroni post hoc
tests for subsequent between-group comparisons. To evaluate any
changes (e.g., sensitization) in drug effects across sessions 1–5,
data within each group were also analyzed using a one-factor,
repeated measures ANOVA. Data from the challenge test were
analyzed using a single-factor ANOVA followed by Bonferroni
post hoc tests for between-group comparisons. Paired-samples t-
tests were also used to compare data from the challenge test to
data from session 1 for each group. In this and other experiments,
p-values 0.05 were considered statistically significant.
Experiment 2
Serum nicotine concentrations and brain: serum nicotine
concentration ratios were analyzed using separate one-way
ANOVAs with group as a factor, followed by Bonferroni post
hoc tests comparing the adult group administered 0.5 mg/kg
nicotine to the adolescent groups administered 0.5 mg/kg or
1.0 mg/kg nicotine. Data for brain nicotine concentrations were
not normally distributed and were therefore analyzed using a
one-way Kruskal-Wallace test followed by Dunn’s post hoc test.
Experiment 3
Total somatic signs during sessions 1 and 2 in adults and
adolescents were analyzed using a three-factor ANOVA with age
and group as between-subject factors, and session as a within-
session factor. Data for each age were subsequently analyzed using
two-factor (group  session) ANOVAs followed by Bonferroni
post hoc tests for comparisons between groups.
To evaluate the effects of nicotine alone on somatic signs in
adolescents, data for the adolescent Nic 1.0 + Sal group were
compared to data from the adolescent Sal + Sal group using a
two-factor (group  session) ANOVA followed by a Bonferroni
post hoc test for comparisons between groups. This analysis could
not be included in the between-age comparison described above
because a group of adults receiving nicotine alone was not tested.
RESULTS
Experiment 1: Effects of Acute
Mecamylamine, Nicotine, and Their
Combination on Somatic Signs
in Adolescents
Sessions 1–5
Single or repeated injections of mecamylamine alone (1.5 or
3.0 mg/kg, s.c.) elicited somatic signs in adolescent rats, but
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FIGURE 1 | Effects of acute mecamylamine, nicotine, and their combination on somatic signs in adolescents. Mean (SEM) total number of somatic
signs during each test session in Experiment 1. For clarity, data from the Nic + Mec 1.5 and Sal + Mec 1.5 groups are graphed separately in (B). Data from the Sal
+ Sal group are included in both (A) and (B). C = Challenge test conducted 1 week after session 5. **Significantly different from Sal+ Sal group, p < 0.01.
this effect was not influenced by 2 h pretreatment with nicotine
(0.5 mg/kg, s.c.; Figures 1A,B). There were significant main
effects of group [F(5,25) = 19.3, p < 0.0001] and session
[F(4,104)= 6.7, p< 0.0001] on somatic signs during sessions 1–5,
but no significant group session interaction. Somatic signs were
elevated in the Nic 0.5 +Mec 3.0, Sal +Mec 3.0, Nic 0.5 +Mec
1.5, and Sal + Mec 1.5 groups compared to the Sal + Sal group
across sessions 1–5 (Bonferroni t = 3.8–6.9, ps < 0.01). No other
significant differences between groups were observed.
A one-factor, repeated measures ANOVA within each group
indicated a trend toward an effect of session for the Sal + Mec
1.5 group [F(4,16) = 2.9, p = 0.057] and the Sal +Mec 3.0 group
[F(4,16) = 2.5, p = 0.098], reflecting a tendency for the effects of
mecamylamine alone to increase across repeated injections (see
Figures 1A,B). There was no effect of session in any other group.
Challenge Test
Due to malfunction of the video recording equipment, data were
not available for three rats (one each from the Sal + Sal, Nic 0.5
+ Sal, and Nic + Mec 1.5 groups). Analysis of data from the
remaining animals indicated a significant effect of group during
the challenge test [F(5,52) = 14.0, p < 0.0001]. The Nic 0.5 +
Mec 3.0 and Sal + Mec 3.0 groups exhibited a greater number
of signs than the Sal + Sal group (t = 5.0 or 5.4, ps < 0.01;
Figure 1A), but did not differ from each other. No other group
differed significantly from the Sal + Sal group (Figures 1A,B).
Somatic signs during the challenge test did not differ from those
during session 1 for any group (all p-values> 0.05).
Experiment 2: Serum and Brain Nicotine
Levels in Adolescents and Adults Following
Acute Nicotine
Analysis of data from adults administered 0.5 mg/kg nicotine
and adolescents administered 0.5 or 1.0 mg/kg nicotine indicated
significant effects of group on serum [F(5,21)= 37.3, p< 0.0001]
and brain (Kruskal-Wallis H = 18.5, p < 0.001) nicotine levels
collected 2 h post-injection. Serum and brain nicotine levels
were lower in adolescents receiving 0.5 mg/kg nicotine compared
to those in adults receiving the same dose (p < 0.05 or 0.01;
Figures 2A,B). In contrast, serum nicotine levels in adolescents
administered 1.0 mg/kg nicotine did not differ from those
in adults administered 0.5 mg/kg nicotine (Figure 2A). Brain
nicotine levels in adolescents administered 1.0 mg/kg nicotine
were slightly higher than those in adults administered 0.5 mg/kg
nicotine (see Figure 2B), but this difference was not significant
(p = 0.10). There was also a significant difference in brain:serum
nicotine concentration ratios between groups [F(5,21) = 39.9,
p < 0.0001], with a higher ratio in both adolescent groups
compared to the adult group (Figure 2C, t = 5.2, or 8.9, p< 0.01).
Experiment 3: Effects of Acute
Mecamylamine, Nicotine, and Their
Combination on Somatic Signs
in Adolescents and Adults
Effects of Mecamylamine Alone and Mecamylamine
Combined with Nicotine on Somatic Signs in
Adolescents and Adults
An initial three-factor ANOVA indicated significant effects of age
[F(1,36)= 7.7, p< 0.01] and group [F(2,36)= 41.4, p< 0.0001] on
somatic signs, but no significant effects of session or interactions.
A subsequent two-factor (group  session) ANOVA on data
for adolescents indicated a significant main effect of group
[F(3,19) = 40.7, p < 0.0001], but no effect of session or
group  session interaction (Figure 3A). Somatic signs were
higher in the Nic 1.0 + Mec 2.25 and Sal + Mec 2.25 groups
compared to the adolescent Sal+ Sal group (t= 5.8–9.4, p< 0.01),
but these groups did not differ from one another (Figure 3A).
In adults, there were significant main effects of group
[F(2,21)= 19.5, p< 0.0001] and session [F(1,21)= 4.9, p< 0.05]
on somatic signs, and a significant group  session interaction
[F(2,21) = 3.6, p < 0.05; Figure 3B]. Somatic signs were elevated
in the Nic 0.5 + Mec 2.25 and Sal + Mec 2.25 groups compared
to the adult Sal + Sal group during sessions 1 and 2 (t = 2.7–6.7,
p< 0.05, or 0.01; Figure 3B). Somatic signs were also higher in the
Nic 0.5 +Mec 2.25 group compared to the Sal +Mec 2.25 group
during session 2 (t = 3.4, p< 0.01).
In summary, mecamylamine (2.25 mg/kg) elicited robust
somatic signs in nicotine-naïve adolescents and adults. This effect
was modestly enhanced by acute nicotine pretreatment in adults
but not in adolescents, even when adolescents were administered
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FIGURE 2 | Nicotine levels in adolescents and adults following acute nicotine. Mean (SD) serum (A) and brain (B) nicotine concentrations and brain:serum
nicotine concentration ratios (C) in adult and adolescent rats in Experiment 2. **Significantly different from adults receiving 0.5 mg/kg nicotine, p < 0.01.
FIGURE 3 | Effects of mecamylamine alone and mecamylamine combined with nicotine on somatic signs in adolescents and adults. Mean (SEM)
total number of somatic signs during each test session in adolescents (A) and adults (B) in Experiment 3. *,**Significantly different from Sal+ Sal group for that age,
p < 0.05, 0.01. # Adult Nic 0.5 + Mec 2.25 group significantly different from adult Sal + Mec 2.25 group at that session, p < 0.01.
a higher nicotine dose (1.0 rather than 0.5 mg/kg, s.c.) to account
for age differences in nicotine pharmacokinetics.
Effects of Nicotine Alone in Adolescents
Comparison of data for the adolescent Nic 1.0 + Sal group
(mean  SEM signs during sessions 1 and 2 = 1.8  0.6 and
2.8  1.0, respectively) and the adolescent Sal + Sal group
(data shown in Figure 1A) indicated a significant effect of group
[F(1,9)= 9.0, p< 0.05], but no effect of session or group session
interaction. The two groups did not differ significantly from one
another at either session (p> 0.13).
DISCUSSION
This study evaluated the ability of high-dose mecamylamine to
elicit somatic signs in nicotine-naïve adolescent rats, and the
potential for acute nicotine pretreatment to potentiate this effect
as previously reported in adults. In Experiment 1, mecamylamine
(1.5 or 3.0 mg/kg) elicited somatic signs in adolescents, but
this effect was not potentiated by 2 h pretreatment with acute
nicotine (0.5 mg/kg). In Experiment 2, 2 h pretreatment with
1.0 mg/kg nicotine produced serum nicotine levels in adolescents
that were similar to those observed in adults administered
0.5mg/kg nicotine, thereby identifying appropriate nicotine doses
for an initial age comparison. In Experiment 3, mecamylamine
(2.25 mg/kg) elicited somatic signs in adolescents and adults. This
effect was modestly enhanced in adults administered 0.5 mg/kg
nicotine, but not in adolescent rats administered 1.0 mg/kg
nicotine.
These studies are the first to examine the effects of acute
mecamylamine, nicotine, and their combination on somatic
signs in adolescent rats. While such effects have previously
been studied in adults (Harris et al., 2013), our findings could
not be predicted based on these data given the important age
differences in the effects of pharmacological manipulation of
nAChRs (e.g., Shram et al., 2006, 2008a; Torres et al., 2008).
Our findings emphasize the need to consider the presence of
somatic signs when designing and interpreting studies involving
administration of high mecamylamine doses to adolescent
rodents. This phenomenon would most obviously impact studies
in which somatic signs are used to measure mecamylamine-
precipitated withdrawal in rats receiving a chronic nicotine
infusion, but could also impact behavior in other models (see
Malin et al., 1994). Furthermore, our findings suggest that the
effects of mecamylamine on somatic signs in adolescents should
be equally considered regardless of whether animals are also
exposed to acute nicotine.
Mecamylamine is being evaluated as a treatment for tobacco
dependence and other disorders in clinical populations that
include adolescents and young adults (Shytle et al., 2002;
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Bacher et al., 2009; Nickell et al., 2013). To the extent that
effects of mecamylamine alone on somatic signs are relevant to
mecamylamine’s adverse side effects in humans (Harris et al.,
2013), our findings raise the possibility that these effects may
be potentiated by concurrent nicotine exposure in adults but
not adolescents. Further use of these models could lead to
new approaches for reducing mecamylamine’s side effects and
facilitating its use as a putative pharmacotherapy.
In addition to acting as a non-selective antagonist at nAChRs,
mecamylamine can have other neurobiological effects including
blockade of glutamatergic N-methyl-D-aspartate (NMDA)
receptors (Omori et al., 1988; Papke et al., 2001) or increases
in brain serotonin levels (Kenny et al., 2000; Ma et al., 2006). It is
unlikely that these effects account for mecamylamine’s elevation
of somatic signs, however, as NMDA receptor antagonists and
serotonin agonists do not elicit somatic signs in drug-naïve
rats (Fundytus and Coderre, 1994; Harrison et al., 2001) and
can actually suppress somatic signs during withdrawal from
chronic exposure to nicotine or other drugs (Higgins et al., 1992;
Fundytus and Coderre, 1994; Ohmura et al., 2011). The ability of
mecamylamine to elicit somatic signs in nicotine-naïve rodents
therefore most likely reflects antagonism of endogenous nAChRs,
at least in part.
We reported that the effects of 3.0 mg/kg mecamylamine
on somatic signs in adults were enhanced following a single
nicotine injection (0.5 mg/kg, s.c.) (Harris et al., 2013).
Although a significant enhancement of the effects of 2.25 mg/kg
mecamylamine on some individual categories of signs (e.g.,
abdominal constrictions) occurred in adults following a single
nicotine injection in Experiment 3 (data not shown), reliable
enhancement of mecamylamine’s effects on total somatic signs
were only observed after a second nicotine injection (see
Figure 3B). While the use of different mecamylamine doses
across studies represents the most obvious explanation for this
discrepancy, it could also reflect variability within the model due
to cohort effects, reliance on an observer-rated measure, or other
factors. Regardless, both data sets show that mecamylamine’s
effects on somatic signs can be modestly potentiated following
a limited number of acute nicotine injections in adult rats.
We have proposed that an enhancement of mecamylamine’s
effects on somatic signs following acute nicotine exposure may be
relevant to nicotinewithdrawal (Harris et al., 2013), similar to how
other authors have interpreted increased antagonist sensitivity
following acute exposure to other drugs (e.g., morphine; Adams
and Holtzman, 1990; Easterling and Holtzman, 1997; Schulteis
et al., 1997, 1999). In support of this interpretation, the diminished
sensitivity of adolescents to the effects of nicotine in the
current models parallels the diminished withdrawal sensitivity
of adolescents in traditional models involving chronic nicotine
infusion (O’Dell et al., 2004, 2006; Shram et al., 2008b).
Furthermore, the dosing regimen used for the Nic + Mec
3.0 group in Experiment 1 elicits elevations in intracranial
self-stimulation thresholds (anhedonia-like behavior) in adult
rodents (Harris et al., 2013), which is a well establishedmeasure of
withdrawal from chronic nicotine exposure (Epping-Jordan et al.,
1998; Watkins et al., 2000; Roiko et al., 2009). Nonetheless, the
relevance of the current effect to nicotine withdrawal should be
confirmed using a range of validation criteria (e.g., blockade by
pharmacotherapies that relieve nicotine withdrawal in smokers
such as bupropion; Malin et al., 1992, 2006; Malin and Goyarzu,
2009).
Alternatively, the ability of nicotine pretreatment to enhance
mecamylamine’s effects on somatic signs in adults may be
unrelated to nicotine withdrawal. For example, to the extent that
mecamylamine’s effects reflect general malaise or aversion (Malin
et al., 1994), this phenomenon might be better described as a
nicotine-induced potentiation ofmecamylamine’s aversive effects.
Viewed from this perspective, our demonstration of reduced
sensitivity of adolescents would complement studies indicating
that adolescents are relatively insensitive to the acute aversive
effects of nicotine itself (Wilmouth and Spear, 2004; Shram et al.,
2006; Torres et al., 2008). Further research is clearly needed to
better understand the nature of the interaction between acute
nicotine and mecamylamine on somatic signs.
The lower serum and brain nicotine levels in adolescents versus
adults following injection of 0.5 mg/kg nicotine in Experiment
2 is consistent with recent findings (Vieira-Brock et al., 2013;
Craig et al., 2014). We also found higher brain:serum nicotine
concentration ratios in adolescents compared to adults, suggesting
greater penetration of nicotine into brain. This phenomenon,
which was also reported in (Craig et al., 2014), suggests a potential
mechanism for the enhanced rewarding effects of nicotine
reported in adolescent rodents in some studies (Shram et al.,
2006; O’Dell, 2009). More generally, the current pharmacokinetic
data emphasize the need to consider between-age differences in
nicotine pharmacokinetics when comparing the effects of nicotine
in adolescent and adult animals.
In conclusion, this study demonstrates that mecamylamine can
elicit somatic signs in adolescent rats in either the presence or
absence of acute nicotine. Further development of these models,
including evaluation of age differences across a range of nicotine
and mecamylamine doses and extension of these models to other
behavioral effects of mecamylamine alone (e.g., suppression of
operant responding), is warranted.
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